Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd reported earnings results for the half year ended June 30, 2022. For the half year, the company reported sales was CNY 51.86 million compared to CNY 77.03 million a year ago. Revenue was CNY 51.86 million compared to CNY 77.21 million a year ago.

Net loss was CNY 21.26 million compared to CNY 6.15 million a year ago. Basic loss per share from continuing operations was CNY 0.1745 compared to CNY 0.0505 a year ago. Diluted loss per share from continuing operations was CNY 0.1745 compared to CNY 0.0505 a year ago.